SIGA Technologies, Inc.
NGM: SIGALive Quote
About SIGA Technologies, Inc.
Healthcare
Drug Manufacturers - Specialty & Generic
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
📊 Fundamental Analysis
SIGA Technologies, Inc. demonstrates exceptional profitability, with a profit margin of 24.6%.
The company recently reported -95.3% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is 11.2%, which suggests room for improvement in capital utilization.
At a current price of $4.36, SIGA currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $4.33 - $9.62).
💰 Valuation Insight
SIGA trades at a 45.5% discount (PE: 13.63), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$314.87M
Trailing P/E
13.63
Forward P/E
2.97
Beta (5Y)
1.06
52W High
$9.62
52W Low
$4.33
Avg Volume
620K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App